# A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL

> **NCT05265975** · PHASE1,PHASE2 · TERMINATED · sponsor: **Antengene Corporation** · enrollment: 54 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma
- Indolent Non-Hodgkin Lymphoma

## Interventions

- **DRUG:** ATG-010
- **DRUG:** Lenalidomide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT05265975
- **Lead sponsor:** Antengene Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-04-07
- **Primary completion:** 2024-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** The adjustment of the sponsor's research and development strategy
- **Last updated:** 2025-06-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05265975

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05265975, "A Study of ATG-010 in Combination With Lenalidomide and Rituximab (R2) in Adults With DLBCL and iNHL". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT05265975. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*